| BIOCRYST PHARMACEUTICALS |
| USA |
| Gesundheit |
| US09058V1035 / 896047 |
| BO1 (Frankfurt) / BCRX (NASDAQ) |
| FRA:BO1, ETR:BO1, BO1:GR, NASDAQ:BCRX |
| - |
| https://www.biocryst.com/ |
|
BioCryst Pharmaceuticals Inc. is a biotechnology company specializing in the research, development, and commercialization of novel small-molecule drugs that target key enzymes in infectious and inflammatory diseases. Leveraging expertise in biology, ..
>Volltext.. |
| 2124.39 Mio. EUR |
| 2661.39 Mio. EUR |
| 778.46 Mio. EUR |
| 279.53 Mio. EUR |
| -402.52 Mio. EUR |
| -1.52 EUR |
| 754.17 Mio. EUR |
| 151.56 Mio. EUR |
| 259.96 Mio. EUR |
| 1.22 |
| 64.72% |
| -702.02% |
| - |
| - |
| - |
| - |
| BIOCRYST |
| 24.07.26 |
|